Anavex Life Sciences Corp (AVXL)

[Investor2014]

Group2 starts the decent at about 54 weeks, then following albeit from a higher base more or less the expected SOC trend. Group1 continues to show stabilised improvement and is pretty certain to have averaged up the timing of the Group2 decline.

Subject to the limitations of a very small open label trial, it looks like APOE3 Alleles is a key determinant factor for response to A2-73.

If the P2a results are reflective of the P2b/3 final analysis, then certainly there will be some patients that will see clinically meaningful benefits well over SOC. That's the quite plausible hope, which IMO is likely to require a PM P3 trial.